Actinium Pharmaceuticals, Inc. — Director's Dealing 2017

Mar 16, 2017

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Actinium Pharmaceuticals, Inc. (ATNM)
CIK: 0001388320
Period of Report: 2017-03-16

Reporting Person: Berger Mark Stanley (Chief Medical Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Options to purchase common stock	$1.04	2027-01-17	Common Stock (325000)		Direct

Footnotes

F1: Options granted on January 17, 2017 to purchase an aggregate of 325,000 shares of common stock. A total of 28% of the options will vest one year from the grant date, and the remaining 75% shall vest in equal increments of 2% per month of the initial option grant over the following three year period.